Not Yet RecruitingNot Applicable

Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms

100 participantsStarted 2025-06-10

Plain-language summary

The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks. * Patients with no prior diagnosis of IBD or IBS. * Patients willing to provide informed consent and comply with study requirements. * Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels Exclusion Criteria: * Patients with a confirmed diagnosis of IBD and currently on treatment. * Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens. * Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders. * Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks. * Pregnant or lactating women.

What they're measuring

efficacy of myeloperoxidase for differentiating irritable bowel syndrome from inflammatory bowel disease.

Timeframe: baseline

Trial details

NCT IDNCT07016529

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-10

View on ClinicalTrials.gov More Irritable Bowel Syndrome (IBS) trials